Paricalcitol may increase the arrhythmogenic activities of Proscillaridin. The serum concentration of Paricalcitol can be increased when it is combined with Ceritinib. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin. Chlorothiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Idelalisib. The metabolism of Paricalcitol can be decreased when combined with Crizotinib. The metabolism of Paricalcitol can be decreased when combined with Dronedarone. The serum concentration of Paricalcitol can be increased when it is combined with Netupitant. The metabolism of Paricalcitol can be increased when combined with Nevirapine. The serum concentration of Paricalcitol can be increased when it is combined with Simeprevir. The risk or severity of adverse effects can be increased when Calcium lactate is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Siltuximab. The metabolism of Paricalcitol can be decreased when combined with Venlafaxine. The serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox. The serum concentration of Paricalcitol can be decreased when it is combined with St. John's Wort. The metabolism of Paricalcitol can be decreased when combined with Ziprasidone. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcipotriol. The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Atomoxetine. The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane. The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Sarilumab. The serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole. The metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole. The serum concentration of Paricalcitol can be increased when it is combined with Boceprevir. The metabolism of Paricalcitol can be decreased when combined with Fluconazole. Paricalcitol may increase the arrhythmogenic activities of Oleandrin. The metabolism of Paricalcitol can be increased when combined with Pentobarbital. The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol. Hydroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Mifepristone. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol. The metabolism of Paricalcitol can be decreased when combined with Isradipine. The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine. The metabolism of Paricalcitol can be decreased when combined with Ticlopidine. The serum concentration of Paricalcitol can be increased when it is combined with Telithromycin. The serum concentration of Paricalcitol can be increased when it is combined with Nefazodone. Trichlormethiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Mineral oil. The metabolism of Paricalcitol can be decreased when combined with Rucaparib. The serum concentration of Paricalcitol can be increased when it is combined with Amiodarone. The serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Ergocalciferol. Polythiazide may increase the hypercalcemic activities of Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Deslanoside. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcidiol. The risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Doxycycline. The metabolism of Paricalcitol can be increased when combined with Phenobarbital. The serum concentration of Paricalcitol can be increased when it is combined with Atazanavir. The serum concentration of Paricalcitol can be increased when it is combined with Saquinavir. The metabolism of Paricalcitol can be increased when combined with Lumacaftor. The metabolism of Paricalcitol can be increased when combined with Primidone. The metabolism of Paricalcitol can be decreased when combined with Bortezomib. The serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab. The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol. The serum concentration of Paricalcitol can be increased when it is combined with Darunavir. The serum concentration of Paricalcitol can be increased when it is combined with Palbociclib. The serum concentration of Paricalcitol can be increased when it is combined with Fusidic Acid. The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. The metabolism of Paricalcitol can be decreased when combined with Diltiazem. Indapamide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Fosaprepitant. The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol. Chlorthalidone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Osimertinib. The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol. Quinethazone may increase the hypercalcemic activities of Paricalcitol. Methyclothiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Stiripentol. Bendroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Orlistat. The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine. The metabolism of Paricalcitol can be decreased when combined with Delavirdine. The metabolism of Paricalcitol can be increased when combined with Rifapentine. The serum concentration of Paricalcitol can be increased when it is combined with Dasatinib. The metabolism of Paricalcitol can be decreased when combined with Sildenafil. The metabolism of Paricalcitol can be decreased when combined with Erythromycin. The metabolism of Paricalcitol can be decreased when combined with Ranolazine. The metabolism of Paricalcitol can be decreased when combined with Clotrimazole. The serum concentration of Paricalcitol can be increased when it is combined with Indinavir. The metabolism of Paricalcitol can be decreased when combined with Verapamil. The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Isavuconazonium. Cyclopenthiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide. Paricalcitol may increase the arrhythmogenic activities of Digitoxin. The metabolism of Paricalcitol can be decreased when combined with Fluvoxamine. The metabolism of Paricalcitol can be increased when combined with Fosphenytoin. Metolazone may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Imatinib. The metabolism of Paricalcitol can be increased when combined with Carbamazepine. The serum concentration of Conivaptan can be increased when it is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Telaprevir. The metabolism of Paricalcitol can be increased when combined with Phenytoin. The metabolism of Paricalcitol can be decreased when combined with Clemastine. The metabolism of Paricalcitol can be decreased when combined with Nilotinib. The serum concentration of Paricalcitol can be increased when it is combined with Lopinavir. The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Luliconazole. The serum concentration of Paricalcitol can be increased when it is combined with Itraconazole. The metabolism of Paricalcitol can be decreased when combined with Olaparib. The serum concentration of Paricalcitol can be increased when it is combined with Voriconazole. Paricalcitol may increase the arrhythmogenic activities of Ouabain. The metabolism of Paricalcitol can be increased when combined with Rifabutin. The metabolism of Paricalcitol can be decreased when combined with Fosamprenavir. Hydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin. The metabolism of Paricalcitol can be decreased when combined with Cyclosporine. The serum concentration of Paricalcitol can be decreased when it is combined with Vemurafenib. The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam. The serum concentration of Paricalcitol can be increased when it is combined with Posaconazole. Danazol may increase the hypercalcemic activities of Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Acetyldigitoxin. The serum concentration of Paricalcitol can be increased when it is combined with Cobicistat. The metabolism of Paricalcitol can be decreased when combined with Lovastatin. The serum concentration of Paricalcitol can be increased when it is combined with Aprepitant. The metabolism of Paricalcitol can be increased when combined with Rifampicin. Paricalcitol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Bosentan. The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib.